Blog Posts by Tag: Molecular
Considerations When Selecting an LIS for Gynecologic Cytology and Molecular Testing
Laboratories leaders investigating LIS solutions for Gynecologic Cytology and Molecular testing need dynamic solutions that meet all productivity and efficiency goals and regulatory requirements. Other essential factors include cytotech reporting, automated quality control review and reporting, pathology oversight and reporting, Bethesda reporting guidelines, management reporting, lookback...
Laboratory Test Claim Denials and Appeals Trends
I recently had the privilege of presenting an in-person workshop in conjunction with The Dark Report Executive War College on Laboratory and Pathology Management. The workshop was on the topic of “Latest Trends and Denials Involving Lab Test Claims.” In this session, I shared XIFIN insights into payor behavior changes and shifting claims processing protocols and highlighted the importance of a...
Pathology Laboratories Need Unique LIS Capabilities
Anatomic pathology laboratories receive multiple specimen types including pathology, IHC, molecular, next-gen sequencing, FLOW, cytogenetics, FISH, clinical trials, and specialty testing. This is why anatomic pathology laboratories require a sophisticated laboratory information system (LIS) with enhanced capabilities that can manage everything from routine to highly complex cases. The right...
Three Questions You Should Be Asking to Determine if the No Surprises Act Applies to You
How do the billing protections established under the No Surprises Act impact my group?This is what everyone is asking. It’s a very complex question that isn’t answered with a simple yes or no. However, listed below are three questions you should ask to determine if any of your services are impacted by the No Surprise Act legislation.* Is the...
No Surprises Act: Your Top Questions Answered - Part 2
This blog is part two of a blog series focusing on answering the most common questions regarding the No Surprises Act. View Part One, which focused on questions related to providing a good faith estimate and obtaining patient consent.The No Surprises Act (NSA) — which provides patient protections by addressing surprise billing and banning balance billing — has many people wondering which parts of...
An LIS Built to Support the Future of Diagnostics
The pandemic has taught the lab industry many valuable lessons. As an industry we need to be nimble and prepared to expand our operations rapidly, not only to manage larger volumes of testing but new diagnostic tests, as well.The laboratory information system (LIS) plays a vital role in test menu expansion, from receiving electronic orders or manually accessioning cases to providing an ordering...
No Surprises Act: Your Top Questions Answered - Part 1
The No Surprises Act (NSA), which went into effect on January 1, has many providers scrambling. The No Surprises Act provided protections for patients who unknowingly receive care from an out-of-network provider by addressing surprise billing and banning balance billing. Implementing the requirements of the No Surprises Act will require a new level of coordination between providers, payors, and...
Integrating Informatics for Clinical-Genomic Collaboration and Analysis
I recently had the pleasure of co-authoring an article in Oncology Practice Management. The article, titled “An Integrated Informatics Approach for Clinical-Genomic Knowledge Sharing and Analysis” outlines the design of a real-time registry that aggregates heterogeneous clinical and genomic data (along with other molecular results) in a unified structure to identify, vet, and fulfill...
- ‹ previous
- 2 of 5
- next ›